TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31371616

Group type: EXPERIMENTAL
Intervention: DS‐Cav1 (stabilized subunit vaccine candidate)
Number of subjects: 0
Study: 28760535

Group type: EXPERIMENTAL
Intervention: 18.8 mg dose of AMP XR-ODT with 4% ethanol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 18.8 mg dose of AMP XR-ODT with 20% ethanol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 18.8 mg dose of AMP XR-ODT with 40% ethanol
Number of subjects: 32

Group type: COMPARATOR
Intervention: 18.8 mg dose of AMP XR-ODT with deionized water
Number of subjects: 32
Study: 26185766

Group type: EXPERIMENTAL
Intervention: Intramuscularly administered drotaverine hydrochloride (40 mg)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (no drotaverine)
Number of subjects: 230
Study: 23384160

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study: 21387350

Group type: EXPERIMENTAL
Intervention: Single-dose administration of 0.5 mg metolazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose administration of 1 mg metolazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-dose administration of 2 mg metolazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of 1 mg metolazone
Number of subjects: 0
Study: 19409085

Group type: EXPERIMENTAL
Intervention: Interactive group sessions (n = 127) over 4 months
Number of subjects: 250

Group type: COMPARATOR
Intervention: Single, non-interactive health education session (n = 123)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Interactive group sessions (n = 127)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Regular self-weighers in the intervention group
Number of subjects: 250

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 250

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 250
Study: 17851785

Group type: EXPERIMENTAL
Intervention: Ligasure vessel-sealing system
Number of subjects: 124

Group type: COMPARATOR
Intervention: Conventional hand tie method
Number of subjects: 124
Study: 15490757

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Pyrimethamine‐sulfadoxine (PS)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: CQ plus chlorpheniramine (CQCP)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: PS combined with CQ or AQ (COM)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: PS combined with probenecid (PPS)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Halofantrine (HF)
Number of subjects: 1048

Group type: COMPARATOR
Intervention: CQ
Number of subjects: 1048

Group type: COMPARATOR
Intervention: CQCP
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Gametocyte carriage
Number of subjects: 1048
Study: 12002908

Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg, twice daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study: 9054280

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (11 mg for 1 week and then ≤ 22 mg for 3 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 7697691

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg plus hydrochlorothiazide 12.5 mg once daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: Benazepril alone (10 mg once daily)
Number of subjects: 93
Study: 3316297

Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hand instrumentation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study: 31493013

Group type: EXPERIMENTAL
Intervention: Mineral water bath plus physical therapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Mud application procedures plus physical therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: KOOS questionnaire
Number of subjects: 92
Study: 31343477

Group type: EXPERIMENTAL
Intervention: Micro-bubble detection test (M group)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Smooth saline injection test (S group)
Number of subjects: 300
Study: 28025582

Group type: EXPERIMENTAL
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 785

Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone (Vd)
Number of subjects: 785
Study: 24621064

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation (500 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23909930

Group type: EXPERIMENTAL
Intervention: Early multidisciplinary assessment by a physiotherapist, a psychotherapist, and an occupational therapist within a week.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 33
Study: 21936492

Group type: EXPERIMENTAL
Intervention: Solar disinfection (SODIS) of drinking water
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1089
Study: 19808924

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy, exenatide, and daclizumab
Number of subjects: 20
Study: 16702822

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (20 mg/day)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Amlodipine besylate (5 mg/day)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 12890955

Group type: EXPERIMENTAL
Intervention: Tramadol alone (20 mg loading dose, continuous infusion of 1 mg/ml tramadol at 8 ml/h)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Bupivacaine alone (20 ml bupivacaine 0.125% loading dose, continuous infusion of 8 ml/h)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of tramadol and bupivacaine (20 mg tramadol loading dose, 20 ml bupivacaine 0.125% loading dose, continuous infusion of 1 mg/ml tramadol in 20 ml bupivacaine 0.125% at 8 ml/h)
Number of subjects: 51
Study: 10655253

Group type: COMPARATOR
Intervention: Nadolol (40-160 mg/d)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Nadolol plus isosorbide mononitrate (10-20 mg 3 times per day)
Number of subjects: 146
Study: 8737763

Group type: EXPERIMENTAL
Intervention: Controlled release oxybutynin tablet (10 mg) after a high fat breakfast
Number of subjects: 23

Group type: COMPARATOR
Intervention: Controlled release oxybutynin tablet (10 mg) in fasting subjects
Number of subjects: 23
Study: 1329480

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Lisinopril, enalapril, captopril, digoxin
Number of subjects: 1000
Study: 3858304

Group type: EXPERIMENTAL
Intervention: Nicotine-containing chewing gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-smokers (no gum)
Number of subjects: 0
Study: 30264745

Group type: EXPERIMENTAL
Intervention: Topical benzoyl peroxide 2.5% gel with a low glycemic load diet
Number of subjects: 84

Group type: COMPARATOR
Intervention: Topical benzoyl peroxide 2.5% gel with a normal diet
Number of subjects: 84
Study: 30558645

Group type: EXPERIMENTAL
Intervention: Tafamidis (T-T group)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (P-T group)
Number of subjects: 125
Study: 27046654

Group type: EXPERIMENTAL
Intervention: Participatory organizational-level intervention focusing on the core task at work
Number of subjects: 3039

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3039
Study: 25041917

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB) angioplasty
Number of subjects: 40

Group type: COMPARATOR
Intervention: Uncoated balloon angioplasty
Number of subjects: 40
Study: 22421647

Group type: EXPERIMENTAL
Intervention: Low-fluence QSNYL (Group A)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Glycolic acid peel (Group B)
Number of subjects: 75

Group type: COMPARATOR
Intervention: High-fluence QSNYL (Group C)
Number of subjects: 75
Study: 20632453

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN‐alpha) therapy
Number of subjects: 474
Study: 18760148

Group type: EXPERIMENTAL
Intervention: Levodopa (100mg of levodopa plus 25mg of carbidopa)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 16398595

Group type: EXPERIMENTAL
Intervention: 2400 mg Chinese red yeast rice (CRYR)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 20 mg lovastatin
Number of subjects: 11
Study: 12053590

Group type: EXPERIMENTAL
Intervention: Triamcinolone (400 mg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Montelukast (5 or 10 mg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Nedocromil (16 mg)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Formoterol (24 micrograms)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 10607712

Group type: EXPERIMENTAL
Intervention: 480 microg granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: G-CSF in vitro
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 10
Study: 8609227

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (30 ng/kg per min) for 3 hours (EPI-3)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (30 ng/kg per min) for 24 hours (EPI-24)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (baseline before epinephrine infusion)
Number of subjects: 17
Study: 1360807

Group type: EXPERIMENTAL
Intervention: Mizolastine (5, 10, 20, 40 mg p.o.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hyoscine butylbromide (HBB) (40 mg, s.c.)
Number of subjects: 12
Study: 6140340

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 22
Study: 31035309

Group type: EXPERIMENTAL
Intervention: Cannabigerol (CBG) 120 mg/kg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Cisplatin only
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Cisplatin and Cannabigerol (CBG)
Number of subjects: 66
Study: 29045584

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 26743812

Group type: EXPERIMENTAL
Intervention: Temperature controlled laminar airflow (TLA) delivered by the Airsonett™ device for one year
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Temperature controlled laminar airflow (TLA)
Number of subjects: 222
Study: 24408989

Group type: EXPERIMENTAL
Intervention: Acute carnosine supplementation (20 mg/kg body weight)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Acute carnosine supplementation
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Explosive athletes
Number of subjects: 235
Study: 22293891

Group type: COMPARATOR
Intervention: Levulan-PDT and placebo (Eucerin as vehicle cream)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Levulan-PDT and imiquimod
Number of subjects: 34
Study: 20871168

Group type: EXPERIMENTAL
Intervention: Triple therapy including Esomeprazole, Amoxicillin, and Furazolidone plus birid triple viable
Number of subjects: 120

Group type: COMPARATOR
Intervention: Triple therapy including Esomeprazole, Amoxicillin, and Furazolidone
Number of subjects: 120
Study: 17600039

Group type: EXPERIMENTAL
Intervention: Enoxaparin (ENOX)
Number of subjects: 3208

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 3208
Study: 15647778

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (n=24)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Candesartan (n=24)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lisinopril (n=22)
Number of subjects: 70
Study: 11422770

Group type: EXPERIMENTAL
Intervention: One unit of blood matched for one HLA-DR antigen (N = 49)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: One unit of mismatched blood (N = 48)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Untransfused (N = 47)
Number of subjects: 144
Study: 9423499

Group type: EXPERIMENTAL
Intervention: Brief Intervention
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 206
Study: 8485789

Group type: EXPERIMENTAL
Intervention: Epidural tramadol (100 mg diluted in 10 ml normal saline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural morphine (4 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epidural tramadol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural morphine
Number of subjects: 20
Study: 2712272

Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine 10 mg, 20 minutes prior to electroconvulsive therapy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (no nifedipine)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 5
Study: 4594580

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 30
Study: 30414841

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injections into epicardial fat pads
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo injections into epicardial fat pads
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) injections
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 60
Study: 28168677

Group type: EXPERIMENTAL
Intervention: Family Peer Advocate (FPA) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study: 26117698

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23583246

Group type: EXPERIMENTAL
Intervention: Standard of care plus lineage-specified stem cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study: 21817198

Group type: EXPERIMENTAL
Intervention: NVP XR 400 mg once daily (plus placebo)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: NVP IR 200 mg twice daily (plus placebo)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: NVP XR
Number of subjects: 1011

Group type: COMPARATOR
Intervention: NVP IR
Number of subjects: 1011
Study: 19565730

Group type: EXPERIMENTAL
Intervention: Acupoint application using Chinese medicine (Zhinanxing, Sanleng, Ezhu) at Zhongji (CV 3), Guanyuan (CV 4), Qihai (CV 6)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Oral administration of Tianqi Tongjing Capsules
Number of subjects: 61
Study: 16442386

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 1186
Study: 15624744

Group type: EXPERIMENTAL
Intervention: 2 mg/kg subcutaneous efalizumab weekly for 12 weeks
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with weekly SC efalizumab after Week 12
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Extended efalizumab therapy
Number of subjects: 339
Study: 11502231

Group type: EXPERIMENTAL
Intervention: Low-fat diet (59.7% carbohydrates, 25.7% fat, 7.8% monounsaturates)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oil-rich diet (37.8% carbohydrates, 44.4% fat, 19.3% monounsaturates)
Number of subjects: 32
Study: 9266866

Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8298070

Group type: EXPERIMENTAL
Intervention: Cardizem SR
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bi-Tildiem
Number of subjects: 24
Study: 3552840

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 23
Study: 29792492

Group type: EXPERIMENTAL
Intervention: Second Step program
Number of subjects: 7419
Study: 27725248

Group type: EXPERIMENTAL
Intervention: 0.4 mg fludrocortisone, a MR agonist
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25435850

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m2 (standard half hour i.v. infusion on days 1 and 8) + Cisplatin 75 mg/m2 on day 2
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Gemcitabine 250 mg/m2 (prolonged 6-hours i.v. infusion on days 1 and 8) + Cisplatin 75 mg/m2 on day 2
Number of subjects: 106
Study: 23031217

Group type: EXPERIMENTAL
Intervention: HBO₂ at 2.4 ATA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham compression (room air at 1.3 ATA)
Number of subjects: 50
Study: 19346279

Group type: EXPERIMENTAL
Intervention: Pregabalin (150-450 mg)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Naltrexone (50 mg)
Number of subjects: 71
Study: 18160532

Group type: EXPERIMENTAL
Intervention: KB2115
Number of subjects: 0
Study: 16636155

Group type: EXPERIMENTAL
Intervention: Coalition processes and structure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Planning and planning products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation actions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activities and collaborations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipated intermediate outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expected asthma related health outcomes
Number of subjects: 0
Study: 12794540

Group type: EXPERIMENTAL
Intervention: Computer-based (CB) training
Number of subjects: 289

Group type: COMPARATOR
Intervention: Instructor-led (IL) training
Number of subjects: 289
Study: 10642013

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including patient education, physician reminders, and audit-with-feedback.
Number of subjects: 4481

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 4481

Group type: EXPERIMENTAL
Intervention: Intervention group compared to control group.
Number of subjects: 4481

Group type: EXPERIMENTAL
Intervention: Adherence to physician mammography referral in the intervention group.
Number of subjects: 4481
Study: 9863127

Group type: EXPERIMENTAL
Intervention: Xinmaitong Capsule (XMTC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Composite Danshen Tablet (CDT)
Number of subjects: 25
Study: 8518020

Group type: EXPERIMENTAL
Intervention: SMF (prednimustine + methotrexate + 5-fluorouracil)
Number of subjects: 153

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide + methotrexate + 5-fluorouracil)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: SMF
Number of subjects: 153

Group type: COMPARATOR
Intervention: CMF
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study: 3120329

Group type: EXPERIMENTAL
Intervention: Sodium deoxycholate preoperatively
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study: 30888202

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 0
Study: 27451920

Group type: EXPERIMENTAL
Intervention: Preparing for Life intervention (biweekly visits from mentors from pregnancy until age 5 years and parent training at age 2 years)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Preparing for Life intervention
Number of subjects: 233
Study: 25637151

Group type: EXPERIMENTAL
Intervention: Benson's relaxation technique (audiotape listened to twice a day for 20 minutes for 8 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 86
Study: 23013888

Group type: EXPERIMENTAL
Intervention: Olmesartan (morning-dose group)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Olmesartan (evening-dose group)
Number of subjects: 218
Study: 21273901

Group type: EXPERIMENTAL
Intervention: 4-hr wheelchair workshop
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 19682654

Group type: EXPERIMENTAL
Intervention: 780-nm laser phototherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser irradiation in cell cultures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser treatment initiated at the earliest possible stage post injury
Number of subjects: 0
Study: 17062304

Group type: EXPERIMENTAL
Intervention: Tizanidine capsules (8 mg) administered with food
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Tizanidine tablets (8 mg) administered with food
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tizanidine capsules (8 mg) administered in fasting state
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tizanidine tablets (8 mg) administered in fasting state
Number of subjects: 96
Study: 12932798

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pemoline (56.25 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10636414

Group type: EXPERIMENTAL
Intervention: Insulin 1.5 mU/kg per minute
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Insulin 3 mU/kg per minute
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8864546

Group type: EXPERIMENTAL
Intervention: Exogenous neuropeptide Y (NPY) 50 nmol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exogenous neuropeptide Y (NPY) 100 nmol
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intranasal pretreatment with NPY (20 nmol)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Oxymetazoline (20 nmol)
Number of subjects: 7
Study: 1346819

Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies (aCEPHA and aCL)
Number of subjects: 597
Study: 6397949

Group type: EXPERIMENTAL
Intervention: Incision plus curettage and primary suture under antibiotic cover
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional incision and drainage
Number of subjects: 83
Study: 29364026

Group type: EXPERIMENTAL
Intervention: 4-week progressive home intrinsic foot muscle (IFM) exercise program performed daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24